Adamas

Adamas

Facts & Stats

  • Aminoadamantanes were first synthesized in the 1950s and include FDA-approved amantadine, rimantadine and memantine.
  • Over 6 million people in the U.S. suffer from chronic neurodegenerative diseases such as dementia and Parkinson’s disease.
  • Adamas is developing Advantaged Therapeutics for dementia and Parkinson’s disease that are designed to provide improved efficacy and tolerability and to simplify daily drug regimens.

 

Syndicate content